Keryx Biopharmaceuticals, Inc.

We are investigating Keryx Biopharmaceuticals, Inc (“Keryx” or the “Company”) (NasdaqCM:KERX) relating to the sale of the Company to Akebia Therapeutics. (“Akebia”). Under the terms of the agreement, Keryx shareholders are only anticipated to receive 0.37433 shares of Akebia for each share of Keryx common stock held.

To receive more information regarding the investigation of Keryx Biopharmaceuticals, Inc. please fill out the form below.